Top

Archives of Gynecology and Obstetrics

Published in:

01-05-2019 | Ovarian Cancer | Gynecologic Oncology

Follicle-stimulating hormone promoted pyruvate kinase isozyme type M2-induced glycolysis and proliferation of ovarian cancer cells

Authors: Shuangdi Li, Xiaoning Ji, Renchen Wang, Yi Miao

Published in: Archives of Gynecology and Obstetrics | Issue 5/2019

Abstract

Purpose

Reprogramming of cell metabolism is essential for tumor progression and the best-studied metabolic phenomenon of cancer cells is aerobic glycolysis, in which pyruvate kinase isozyme type M2 (PKM2) plays a critical role. Follicle-stimulating hormone (FSH) contributes to epithelial ovarian cancer progression and has been shown to regulate cell metabolism in ovaries. The aim of this study was to investigate the interaction between FSH and PKM2 and their effect on aerobic glycolysis and cell proliferation in ovarian cancer.

Methods

SKOV3 and OVCAR3 ovarian cancer cells were treated with FSH at various doses to investigate its effect on cell proliferation and PKM2 expression. siRNA-PKM2-transfected SKOV3 and OVCAR3 cells were treated with FSH to examine whether the changes induced by FSH could be altered by siRNA-PKM2. Glucose and lactate levels were evaluated to observe the change in glycolysis in these cells.

Results

In the current study, FSH upregulated the expression of PKM2 and glycolysis in SKOV3 and OVCAR3 cells. PKM2 knockdown reduced FSH-induced cell growth and glycolysis. Moreover, FSH attenuated apoptosis that was induced by the inhibition of PKM2.

Conclusions

Collectively, the findings of this study indicated that FSH promoted glycolysis in epithelial ovarian cancer cells. Knockdown of PKM2 inhibited aerobic glycolysis and cell proliferation induced by FSH.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442 CrossRef

Drescher CW, Karlan BY (2010) Progress toward ovarian cancer early detection: strategies, guidelines, and clinical trials. Female Patient 35(4):22

Bast RC Jr., Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G (2002) Early detection of ovarian cancer: promise and reality. Cancer Treat Res 107(2):61–97PubMed

Choi JH, Wong AS, Huang HF, Leung PC (2007) Gonadotropins and ovarian cancer. Endocr Rev 28(4):440–461. https://doi.org/10.1210/er.2006-0036 CrossRefPubMed

Yang Y, Zhang J, Zhu Y, Zhang Z, Sun H, Feng Y (2014) Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K/Akt-Snail signaling pathway. Int J Gynecol Cancer 24(9):1564–1574. https://doi.org/10.1097/IGC.0000000000000279 CrossRefPubMed

Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H, Xiong J, Tao X, Yan D, Xi X, Chen X, Yu Y, Bast RC, Zhang Z, Feng Y, Zheng W (2016) Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1alpha/cyclin D1 pathway. Oncogene 35(19):2506–2517. https://doi.org/10.1038/onc.2015.316 CrossRefPubMed

Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41(3):211–218. https://doi.org/10.1016/j.tibs.2015.12.001 CrossRefPubMedPubMedCentral

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013 CrossRef

Warburg O (1956) On respiratory impairment in cancer cells. Science 124(3215):269–270

10.

Payen VL, Porporato PE, Baselet B, Sonveaux P (2016) Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. Cell Mol Life Sci 73(7):1333–1348. https://doi.org/10.1007/s00018-015-2098-5 CrossRef

11.

Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC (2015) Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep 42(4):841–851. https://doi.org/10.1007/s11033-015-3858-x CrossRefPubMed

12.

Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 11(5):325–337. https://doi.org/10.1038/nrc3038 CrossRefPubMed

13.

Chaneton B, Gottlieb E (2012) Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem Sci 37(8):309–316. https://doi.org/10.1016/j.tibs.2012.04.003 CrossRefPubMed

14.

Wong N, De Melo J, Tang D (2013) PKM2, a central point of regulation in cancer metabolism. Int J Cell Biol 2013:242513. https://doi.org/10.1155/2013/242513

15.

Mazurek S (2011) Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 43(7):969–980. https://doi.org/10.1016/j.biocel.2010.02.005 CrossRefPubMed

16.

Wong N, Ojo D, Yan J, Tang D (2015) PKM2 contributes to cancer metabolism. Cancer Lett 356(2 Pt A):184–191. https://doi.org/10.1016/j.canlet.2014.01.031 CrossRef

17.

Miao Y, Lu M, Yan Q, Li S, Feng Y (2016) Inhibition of proliferation, migration, and invasion by knockdown of pyruvate kinase-M2 (PKM2) in ovarian cancer SKOV3 and OVCAR3 cells. Oncol Res 24(6):477–485. https://doi.org/10.3727/096504016X14685034103671 CrossRef

18.

Schulze A, Harris AL (2012) How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491(7424):364–373. https://doi.org/10.1038/nature11706 CrossRefPubMed

19.

Hadoux J, Massard C (2013) Targeting cancer cell metabolism: evidences and perspectives. Oncologie 15(9):467–473CrossRef

20.

Gupta V, Wellen KE, Mazurek S, Bamezai K, Rameshwar N (2014) Pyruvate kinase M2: regulatory circuits and potential for therapeutic intervention. Curr Pharm Des 20(15):2595–2606CrossRefPubMed

21.

Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X (2011) Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 30(42):4297–4306CrossRefPubMed

22.

Romero-Garcia S, Moreno-Altamirano MMB, Prado-Garcia H, Sánchez-García FJ (2016) Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. Front Immunol 7:52CrossRefPubMedPubMedCentral

23.

Zwaans BM, Lombard DB (2014) Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming. Dis Model Mech 7(9):1023–1032CrossRefPubMedPubMedCentral

24.

Slattery ML, Herrick JS, Lundgreen A, Fitzpatrick FA, Curtin K, Wolff RK (2010) Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis 31(9):1604–1611CrossRefPubMedPubMedCentral

25.

Faubert B, Vincent EE, Griss T, Samborska B, Izreig S, Svensson RU, Mamer OA, Avizonis D, Shackelford DB, Shaw RJ (2014) Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc Natl Acad Sci USA 111(7):2554–2559CrossRef

26.

Li B, Simon MC (2013) Molecular pathways: targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin Cancer Res 19(21):5835–5841CrossRefPubMed

27.

Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA 108(10):4129–4134CrossRefPubMed

28.

Li Z, Yang P, Li Z (2014) The multifaceted regulation and functions of PKM2 in tumor progression. Biochem Biophys Acta 1846(2):285–296PubMed

29.

Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452(7184):230–233CrossRefPubMed

30.

Schneider J, Morr H, Velcovsky H, Weisse G, Eigenbrodt E (2000) Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev 24(6):531–535PubMed

31.

Zhou CF, Li XB, Sun H, Zhang B, Han YS, Jiang Y, Zhuang QL, Fang J, Wu GH (2012) Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells. IUBMB Life 64(9):775–782CrossRef

32.

Yuan Y, Guo-Qing P, Yan T, Hong-Lin Y, Gong-Hua H, Cai-Gao Z (2012) A study of PKM2, PFK-1, and ANT1 expressions in cervical biopsy tissues in China. Med Oncol 29(4):2904–2910CrossRefPubMed

33.

Ma Y, Peng J, Liu W, Zhang P, Huang L, Gao B, Shen T, Zhou Y, Chen H, Chu Z (2009) Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol Cell Proteom 8(8):1878–1890CrossRef

34.

Cui R, Shi XY (2015) Expression of pyruvate kinase M2 in human colorectal cancer and its prognostic value. Int J Clin Exp Pathol 8(9):11393–11399PubMedPubMedCentral

35.

Peng X-c, Gong F-m, Zhao Y-w, Zhou L-x, Xie Y-w, Liao H-l, Lin H-j, Li Z-y, Tang M-h, Tong A-p (2011) Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma. PLoS One 6(11):e27309CrossRefPubMedPubMedCentral

36.

Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK, Wickramasinghe J, Nguyen JM, O'Brien SW, Gumireddy K (2017) Follicle-Stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target. Clin Cancer Res 23(2):441–453CrossRefPubMed

37.

Huang Y, Hua K, Zhou X, Jin H, Chen X, Lu X, Yu Y, Zha X, Feng Y (2008) Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. Cell Res 18(7):780–791CrossRefPubMed

38.

Choi J-H, Choi K-C, Auersperg N, Leung PC (2006) Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 66(7):3912–3920CrossRefPubMed

39.

Xu C, Lu X, Yan X, Wang H, Chen S (2012) Effects of PI3 K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer. Zhonghua Fu Chan Ke Za Zhi 47(2):134–138PubMed

40.

Roy SK, Terada DM (1999) Activities of glucose metabolic enzymes in human preantral follicles: in vitro modulation by follicle-stimulating hormone, luteinizing hormone, epidermal growth factor, insulin-like growth factor i, and transforming growth factor β1. Biol Reprod 60(3):763–768CrossRefPubMed

Title: Follicle-stimulating hormone promoted pyruvate kinase isozyme type M2-induced glycolysis and proliferation of ovarian cancer cells
Authors: Shuangdi Li
Xiaoning Ji
Renchen Wang
Yi Miao
Publication date: 01-05-2019
Publisher: Springer Berlin Heidelberg
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: Archives of Gynecology and Obstetrics / Issue 5/2019
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-019-05100-4

At a glance: The STEP trials

Springer Medicine

Follicle-stimulating hormone promoted pyruvate kinase isozyme type M2-induced glycolysis and proliferation of ovarian cancer cells

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2019

Spatulas for entrapment of the after-coming head during vaginal breech delivery

Neurovascular and lymphatic vessels distribution in uterine ligaments based on a 3D reconstruction of histological study: to determine the optimal plane for nerve-sparing radical hysterectomy

Patients’ perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life—a study of the North-Eastern-German Society of Gynecological Oncology

The impact of repetitive oocyte retrieval on the ovarian reserve: a retrospective cohort study

Second-trimester maternal lipid profiles predict pregnancy complications in an age-dependent manner

Long-term effects of prenatal exposure to metformin on the health of children based on follow-up studies of randomized controlled trials: a systematic review and meta-analysis